Frontier Biotechnologies, Inc. (China)

Frontier Biotechnologies, Inc. faced notable volatility on July 17, 2026, with a significant stock decline, contrasting with the broader market. The company has experienced a sharp weekly drop, despite a positive monthly performance. Long-term growth remains modest, raising concerns about financial stability amid high valuations and negative net worth.

Frontier Biotechnologies, Inc. faced a notable decline in its stock today, contrasting with the broader market's performance. Despite recent volatility, the company has demonstrated significant long-term growth, although it grapples with financial challenges such as low return on capital and a negative net worth. Its market capitalization is CNY 3,736 million.

Frontier Biotechnologies, Inc. has seen a notable rise in stock performance, reflecting a 69.35% increase over the past year. Despite this, the company faces challenges, including a low return on capital employed and a negative net worth, while experiencing significant volatility in its stock price.

Frontier Biotechnologies, Inc. has seen notable stock activity, with significant gains over various timeframes, including a 120.66% increase over the past year. However, the company faces challenges such as a low return on capital employed and a negative net worth, indicating a complex financial situation.

Frontier Biotechnologies, Inc. has seen a notable increase in its stock price, outperforming the China Shanghai Composite. The company has demonstrated strong growth over various periods, including a significant year-to-date rise. However, it faces challenges such as a low return on capital employed and a negative net worth.

Frontier Biotechnologies, Inc. has seen a notable rise in stock performance, reaching an intraday high amid a declining market. The company has outperformed the broader market over the past week and year, despite facing challenges in long-term performance and financial sustainability, including reported losses and a negative net worth.

Frontier Biotechnologies, Inc. has seen a notable rise in stock performance, achieving a significant year-to-date increase and a remarkable surge over the past year. However, the company faces challenges, including a low return on capital employed and a negative net worth, despite steady growth in net sales.

Frontier Biotechnologies, Inc. faced a notable decline in stock value, contrasting with broader market trends. Despite an annual gain, the company struggles with low return on capital and negative net worth, raising concerns about management efficiency and growth prospects. Its financial metrics indicate a challenging trading environment.

Frontier Biotechnologies, Inc. has seen a significant rise in its stock today, contrasting with the modest gains of the China Shanghai Composite. Over the past week, the company has outperformed the market, though it has experienced volatility in the last month. Its annual performance remains strong despite underlying challenges.

Frontier Biotechnologies, Inc. has seen significant stock activity, reaching an intraday high and demonstrating impressive annual growth. Despite recent short-term declines, the company operates in the Pharmaceuticals & Biotechnology sector with a notable market capitalization, though it faces financial challenges reflected in its return on equity and debt-equity ratio.

Frontier Biotechnologies, Inc. faced notable volatility, hitting an intraday low and experiencing a significant weekly decline. Despite recent challenges, the company has shown strong annual growth. Operating in the Pharmaceuticals & Biotechnology sector, it has a mid-cap market capitalization but struggles with low return on capital and negative net worth.

Frontier Biotechnologies, Inc. faced a notable decline in stock value, contrasting with the broader market's performance. Despite a significant annual growth rate, the company struggles with low management efficiency and financial challenges, including reported losses and a negative net worth, complicating its market position.

Frontier Biotechnologies, Inc. has seen a notable increase in stock performance, achieving a significant intraday high amid a declining market. While the company has demonstrated impressive annual growth, it faces challenges such as low return on capital and negative net worth, reflecting a complex financial landscape.